GOSS News and Press, Gossamer Bio Inc. From 05/18/20

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other con...

Image source: The Motley Fool. Gossamer Bio Inc   (NASDAQ: GOSS) Q1 2020 Earnings Call May 13, 2020 , 8:30 p.m. ET Operator Continue reading

The following slide deck was published by Gossamer Bio, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Penny Stocks To Watch In The Middle Of The Month Are you looking for some penny stocks to buy ? If you said yes, you’re not alone. This year we’ve seen so much attention on trading penny stocks and for good reason. If you look back at years-past, these small-cap stocks have go...

Gossamer Bio, Inc. (GOSS) Q1 2020 Earnings Conference Call May 12, 2020 16:30 ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujrathi - Co-founder & Chief Executive Officer Luisa Salter-Cid - Chief Scientific Officer Richard Aranda - Senior Vice Pres...

CINCINNATI, May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced a restructuring of their lic...

Gossamer Bio (NASDAQ: GOSS ): Q1 GAAP EPS of -$0.87 misses by $0.12 . Cash, cash equivalents and marketable securities totaled $346.16M Press Release More news on: Gossamer Bio, Inc., Earnings news and commentary, Healthcare stocks news,

- GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed - - GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance forms - - GB004 completed successful Phase 1b in ulcerative colit...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2020 financial resu...

NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action...